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ugust 12, 2013.he goal of this study was to systematically review the peripartum cardiomyopathy (PPCM) literature and determine
the prevalence of pre-eclampsia (PE) in women with PPCM. Secondary analyses included evaluation of the
prevalence of hypertensive disorders, multiple gestations, and multiparity.Background PPCM is a signiﬁcant cause of maternal and infant morbidity and mortality worldwide, yet its etiology remains
unknown. PE is often cited as a risk factor for the development of PPCM and recent research suggests that PE and
PPCM share mechanisms that contribute to their pathobiology. No comprehensive evaluation of the relationship
between PE and PPCM exists.Methods A systematic predetermined search strategy was performed in multiple databases to identify studies
describing 3 women with PPCM. Prevalence rates of PE, hypertension, multiple gestations, and multiparity
were pooled.Results Data from 22 studies (n ¼ 979) were included in this analysis. The pooled prevalence of 22% (95% conﬁdence
interval [CI]: 16% to 28%) was more than quadruple the 5% average worldwide background rate of PE in pregnancy
(p < 0.001). There were no geographic or racial differences detected in the prevalence of PE in women with PPCM.
The rates of hypertension during pregnancy (37% [95% CI: 29% to 45%]) and multiple gestations (9% [95% CI: 7% to
11%]) were also elevated.Conclusions The prevalence of PE, hypertensive disorders, and multiple gestations in women with PPCM is markedly higher than
that in the general population. These ﬁndings support the concept of a shared pathogenesis between PE and PPCM
and highlight the need for awareness of the overlap between these 2 diseases. (J AmColl Cardiol 2013;62:1715–23)
ª 2013 by the American College of Cardiology FoundationPeripartum cardiomyopathy (PPCM) affects women around
the time of childbirth and is marked by unexplained systolic
dysfunction and the development of symptomatic heart
failure (1,2). PPCM affects 1 in 3,000 pregnancies, although
it is more common in women of African descent (3,4) and
can occur in as many as 1% of all pregnancies in certain “hot
spots” such as Haiti and Nigeria (5,6). The outcome is
devastating for both mothers and infants. PPCM accounts
for 5% of heart transplants in U.S. women, an option not
available in most of the world (7). As many as 25% of
women with PPCM in developing countries die within 5
years (8), with an associated infant mortality rate as high asd Center for Vascular Biology Research, Beth
ston, Massachusetts. Dr. Bello is supported by
Institute (T32 5T32HL007374-33). Dr. Arany
, Lung, and Blood Institute and the Ellison
Dr. Rendon has reported that she has no rela-
his paper to disclose.
; revised manuscript received July 29, 2013,50% to 75% (9,10). In the United States, the mortality rate
for women with PPCM approximates 6% for white non-
Hispanic women and is 4-fold higher in women of
African descent (11).
The etiology of PPCM remains enigmatic. Numerous
hypotheses have been proposed, including viral myocarditis,
autoimmunity, and fetal microchimerism. Hull and Hidden
(12) ﬁrst described a connection between postpartum heart
failure and hypertensive heart disease in 1938 when they noted
that >85% of cases of “‘toxic’ postpartal” heart disease were
associated with hypertension, which was double the frequency
seen in their control group. Demakis and Rahimtoola (13),
in their classic 1971 description of PPCM, reported that
“toxemia,” an older term for pre-eclampsia (PE), was detected
in 22% of affected women. Since the publication of these
seminal studies, PE has often been cited as an independent
risk factor for the development of PPCM (14–16), but not
all clinical studies support this conclusion (17).
Recent research suggests that PPCM is a vascular
disease, triggered by late-gestational secretion of potent
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1716antiangiogenic agents from the
placenta and pituitary (18,19).
In this context, the frequently
noted association of PPCM
with PE is of special interest
because PE is similarly caused
by excess secretion of such
antivascular factors from the
placenta (20). Multiple gesta-
tions also have higher circulating
levels of these antiangiogenic
factors and are a risk factor forboth PPCM and PE (21,22). In light of these observations,
the objective of the current paper was to review the PPCM
literature to determine the frequency of association between
PPCM and PE. In secondary analyses, we reviewed the
observed frequency of any hypertensive disorder, as well as
multiple gestations and multiparity in pregnancies affected
by PPCM.Methods
Literature search. The methods and inclusion criteria were
speciﬁed in advance and documented in a protocol (Online
Appendix). We followed the guidelines from MOOSE
(Meta-analyses of Observational Studies in Epidemiology)
(23) and the Cochrane Handbook for Systematic Reviews
(24). Studies were identiﬁed by searching electronic data-
bases, scanning reference lists, and consultation with experts
in the ﬁeld. This search strategy was applied to MEDLINE
(1966 to present), EMBASE (1966 to present), and Web of
Science (1945 to present). Cochrane and DARE (Database
of Abstracts of Reviews of Effectiveness) databases were
reviewed. We used the following search strategy to search
MEDLINE and adapted it for the other databases: “Car-
diomyopathies”[MeSH] OR “Cardiomyopathies”[tiab] OR
“Cardiomyopathy”[tiab]) AND (“Pregnancy”[MeSH] OR
“Pregnancies”[tiab] OR “Gestation”[tiab] OR “pregnan-
cy”[tiab]. The analysis was restricted to articles and ab-
stracts published in English. No publication date restrictions
were imposed. The last search was run on January 7, 2013.
Study selection. Independent screening of articles and
abstracts was performed by 2 authors (Drs. Bello and Rendon)
by using predeﬁned data ﬁelds, including study quality indi-
cators and the following criteria: 1) the publication
described3 women with PPCM; 2) the publication reported
numbers of cases and sample size or the prevalence of PE
and/or hypertensive disorders; and 3) PPCM was deﬁned
according to the 1992 National Heart, Lung, and Blood
Institute Workshop criteria of left ventricular ejection fraction
(LVEF) <45%, fractional shortening <30%, or both (25,26).
Recent deﬁnitions of PPCM have loosened both the
requirements that LVEF be <45% and that presentation
occur within 1 month before or 5 months after delivery.
Nevertheless, we chose to adhere strictly to the National
Institutes of Health criteria promoted by the 1992 NationalHeart, Lung, and Blood Institute workshop because these
criteria remain widely accepted and because the criteria are
more clearly deﬁned. We also extracted data on patient
characteristics, study design, and location. For those articles on
which the 2 data extractors disagreed (n¼ 3), the third author
(A.A.) independently reviewed the articles and made a ﬁnal
decision on the inclusion or exclusion of the study.
For the purpose of the current review, cases described as
PE or eclampsia were grouped as PE, and hypertension
during pregnancy was deﬁned as either chronic hyperten-
sion, gestational hypertension, PE, eclampsia, or hyperten-
sion not otherwise speciﬁed. When there was overlap of
patients between publications, the distinct patients were
included once and analyzed as a single sample (rather than as
2 studies) (15,27).
Statistical analysis. For each included study, the prevalence
of PE and its 95% conﬁdence interval (CI) was calculated. If
a study included an explicit prevalence rate of 0%, we increased
the prevalence of PE to 5% to calculate SEs and CIs. Meta-
analysis was performed by using a variable effects model to
determine thepooled prevalence ofPE inwomenwithPPCM.
The analysis was also stratiﬁed according to country of origin.
Heterogeneity was assessed by using the Cochran’s Q test and
I2 statistics. For the secondary analyses of hypertensive disor-
ders and twins, the heterogeneity was high, and we chose to
display the results in narrative format rather than as a meta-
analysis. Spearman’s correlation was performed to evaluate
the relationship between African descent and PE in women
with PPCM. Statistical analyses were performed by using
Stata/SE version 12.0 (StataCorp, College Station, Texas).
Results
A total of 241 full-text articles and abstracts of primary data
were identiﬁed as potentially relevant publications, and 22
(5,11,14–17,27–42) were included in the primary analysis
(Fig. 1). Table 1 describes the characteristics of the studies
and patients included in the analysis. Overall, 979 patients
were included, approximately one-half of studies were from
the United States, and most were published within the last
decade. Sample size varied from 6 to 110, and the majority of
women were multiparous. The fraction of women of African
descent varied widely, even within the United States.
The overall prevalence of PE varied from a low of 0% (n¼
17) to a high of 78% (n ¼ 38) in the individual studies
(Table 2). The summary estimate of the prevalence of PE
was 22% (95% CI: 16% to 28%) (Fig. 2), which is >4 times
higher than the 3% to 5% average worldwide prevalence
of PE (p < 0.001) (43–46). There was substantial hetero-
geneity among the included studies (Q test, p < 0.001; I2
79%). To investigate potential causes of heterogeneity,
a subgroup meta-analysis looking at the rate of PE by
country was performed. The studies from the United States
had an estimated prevalence of 24% (95% CI: 17% to 32%),
higher than the rest of the world (17% [95% CI: 8% to 26%);
these studies had markedly reduced heterogeneity (Fig. 3).
Figure 1 Process of Study Selection
HTN ¼ hypertension; PE ¼ pre-eclampsia; PPCM ¼ peripartum cardiomyopathy.
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1717A secondary analysis, including an additional 10 studies
(47–56) and excluding 1 study from the primary analysis
because of patient overlap (37), was performed to assess the
prevalence of any hypertensive disorder (preeclamptic or
not), twin/multiple gestations, and multiparity during
pregnancies affected by PPCM (Table 2). There was high
heterogeneity observed among these studies, which
precluded the performance of a formal meta-analysis. The
rates of both hypertensive disorders and twins were elevated
above background rates in women with PPCM. The rate of
any hypertensive disorder ranged from 2% to 83%, with
a weighted average prevalence of 37%, well above the esti-
mated prevalence of 22% to 27% (57). The prevalence of
twins or multiple gestation, when reported (N ¼ 16), ranged
from 0% to 38% with an average of 9%, again higher thanthe average estimated prevalence of 3% (58). Sixty-seven
percent of women with PPCM were multiparous.
PPCM is more common in women of African descent
(4,11,59), raising the possibility that the relationship
between PE and PPCM may differ in this group. Figure 4
displays the rates of PE as a function of prevalence of
African heritage in each of the studies included in the
primary analysis. There was no correlation found between
rates of PE and African heritage in women with PPCM at
the study level (correlation coefﬁcient –0.35, p ¼ 0.4).
Discussion
Our analysis found that patients with PPCM have a preva-
lence of PE >4 times the average global rate expected in the
Table 1 Characteristics of Studies Included in the Meta-Analysis
First Author (Ref. #) Year Country n Mean Age (yrs) African Descent (%)
Amos et al. (14) 2006 United States 55 29 51
Chapa et al. (28) 2005 United States 32 27 78
Chee et al. (41) 2013 Malaysia 8 31 NA
Elkayam et al. (30) 2001 United States 44 29 36
Elkayam et al. (29) 2005 United States 100 31 19
Felker et al. (17) 2000 United States 42 29 46
Fett et al. (5) 2005 Haiti 98 32 100
Gunderson et al. (16) 2011 United States 110 NA 29
Harper et al. (11) 2012 United States 79 NA 59
Hasan et al. (31) 2010 Pakistan 32 32 0
Horgan et al. (42) 2013 Ireland 12 35 0
Horne et al. (32) 2011 United States 71 30 7
Mandal et al. (36) 2011 India 36 NA NA
Modi et al. (37) 2005 United States 30 23 80
Pillarisetti et al. (39) 2011 United States 81 30 60
Samonte et al. (38) 2012 Philippines 9 29 NA
Sebillotte et al. (33) 2010 Martinique 13 30 100
Shah et al. (40) 2012 Pakistan 61 31 30
Suri et al. (34) 2012 India 28 28 0
Vettori et al. (35) 2011 Brazil 6 27 50
Witlin et al. (15,27) 1997 United States 32 32 75
NA ¼ not available.
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1718general population. The included studies come from coun-
tries around the globe and are representative of the general
population of PPCM. This rate varied by study but was
elevated in all but 2 studies. The ﬁrst study, by Fett et al. (5),
investigated women in Haiti, where the incidence of PPCM
is extraordinarily high, suggesting that the cause of PPCM
in that country may differ from elsewhere. In addition, some
women with PE were excluded from the study (J. Fett,
personal communication, March 2013). The second study
(17) reported a prevalence of 0%, but this may be an under-
estimate of the true prevalence of PE in this cohort because an
earlier study of a subset of the same cohort (60) reported
a prevalence of 11%. These observations underscore an
inherent limitation of meta-analyses, which rely on reported
studies. Nevertheless, the observations suggest that some of
the observed elevated heterogeneity likely relates to the
exclusion of some cases of PE from the studies, and that our
calculated pooled prevalence of PE in PPCM is a conservative
value that likely underestimates the true prevalence.
Historically, many PPCM studies purposefully excluded
women with PE or eclampsia to avoid misclassiﬁcation of
PE-associated pulmonary edema as PPCM (e.g., the study
by Hasan et al. [31]). It is important to appreciate that PE-
associated pulmonary edema is a distinct clinical entity that
occurs in the presence of high blood pressure and increased
cardiac afterload, but unlike PPCM, it occurs despite
a normal ejection fraction. We recommend, however, that
women with PE not be excluded from future studies of
PPCM, in light of their strong association.
The strong epidemiological relationship observed between
PE and PPCM suggests that PE may be part of a pathwaythat leads to impairments in cardiac function. Consistent
with this notion, several studies have recently shown that
women with PE have evidence of diastolic dysfunction, as
well as impaired systolic strain despite preservation of global
systolic function as assessed by ejection fraction (61–63).
Gestational hypertension without PE does not cause similar
cardiac dysfunction, indicating that aspects of PE other than
elevation of blood pressure contribute to cardiac dysfunction
(63,64). Moreover, cardiac dysfunction associated with PE
persists for at least a year, despite normalization of blood
pressure (64).
It is important to note that PPCM is unlikely to be simply
a manifestation of severe PE. LVEF in women with PE,
even if complicated by acute pulmonary edema, is usually
either unchanged or minimally reduced. In contrast, LVEF
is usually severely depressed in women with PPCM. The
results of our meta-analysis indicate that there is an elevated
prevalence of PE in women with PPCM, but it remains true
that up to 80% of women with PPCM have no history of PE
and, conversely, >90% of women with PE do not develop
PPCM. PE thus likely causes cardiac dysfunction directly,
but it is neither necessary nor sufﬁcient to cause PPCM.
Other factors, yet unknown, must coexist to trigger full-
blown cardiac failure.
The strong association between PE and PPCM, and the
evidence that PE causes cardiac dysfunction independently
of PPCM, suggests that the 2 diseases may share mecha-
nisms of pathophysiology. PE is widely accepted to be
a vascular disease (20). The late-gestational placenta of all
pregnancies secretes potent antiangiogenic factors into the
maternal circulation that are greatly up-regulated in women
Table 2
Rates of Hypertensive Disorders, Multiple Gestations, and Multiparity During Pregnancy in Women With
Peripartum Cardiomyopathy
First Author (Ref. #) Year Country n Mean Age (yrs) PE (%)
Any HTN During
Pregnancy (%) Twins or Multiples (%) Multiparous (%)
Amos et al. (14) 2006 United States 55 29 45 56 NA 63
Chapa et al. (28) 2005 United States 32 27 16 16* 13 50
Chee et al. (41) 2013 Malaysia 8 31.2 13 25 38 NA
Elkayam et al. (30) 2005 United States 100 30.7 33 43 13 NA
Elkayam et al. (29) 2001 United States 44 29 23 32 NA 100
Felker et al. (17) 2000 United States 42 29 0 43 12 53
Fett et al. (5) 2005 Haiti 98 32.2 4 19 NA 76
Gentry et al. (55) 2010 United States 28 26 NA 29 NA 58
Gunderson et al. (16) 2011 United States 110 NA 12 50 8 61
Habli et al. (56) 2008 United States 70 29 NA 23 NA NA
Harper et al. (11) 2012 United States 79 NA 28 63 9 NA
Hasan et al. (31) 2010 Pakistan 32 31.8 19 50 6 97
Horgan et al, (42) 2013 Ireland 12 34.7 75 75 17 75
Horne et al. (32) 2011 United States 71 30 25 68 NA NA
Huang et al. (47) 2012 China 52 25.2 NA 12 NA NA
Lampert et al. (51) 1993 United States 15 30 NA 53 NA NA
Mandal et al. (36) 2011 India 36 NA 11 11* NA 61
Modi et al. (54) 2009 United States 44 25.2 NA 45 17 NA
Pillarisetti et al. (39) 2011 United States 81 30 33 33 NA 60
Saﬁrstein et al. (48) 2012 United States 55 31.6 NA 42 15 51
Saltzberg et al. (49) 2012 United States 107 31.2 NA 14 15 66
Samonte et al. (38) 2012 Philippines 9 29 78 78* 11 78
Sebillotte et al. (33) 2010 Martinique 13 30 8 31 15 54
Shah et al. (40) 2012 Pakistan 61 30.9 20 51 8 95
Shani et al. (50) 2008 Israel 25 34 NA 48 2 36
Sliwa et al. (52) 2003 South Africa 100 31.6 NA 2 5 80
Suri et al. (34) 2012 India 28 28.3 25 21 0 NA
Vettori et al. (35) 2011 Brazil 6 26.5 50 83 17 83
Witlin et al. (15,27) 1997 United States 32 31.8 25 69 NA 89
Yang et al. (53) 2002 China 11 28.7 NA 18 NA 27
Overall (95% CI) 37 (29–45) 9 (7–11) 67 (60–74)
*No mention of chronic or gestational hypertension; pre-eclampsia rate was therefore used.
HTN ¼ hypertension; NA ¼ not available; PE ¼ pre-eclampsia.
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1719with PE (65). The most prominent such factor, a soluble
version of the vascular endothelial growth factor receptor-1
(sVEGFR1), binds and neutralizes circulating vascular
endothelial growth factor. At elevated concentrations,
sVEGFR1 disrupts homeostasis in many vascular beds,
including the glomerulus, which leads to the hypertension
and proteinuria that are characteristic of PE (66,67). Recent
evidence from 2 mouse models suggests that PPCM is
similarly a disease of the vasculature (18,19). In 1 model,
which is deﬁcient in peroxisome proliferator-activated
receptor gamma coactivator 1-alpha, sVEGFR1 was sufﬁ-
cient to trigger the development of dilated cardiomyopathy
even in the absence of pregnancy. This pathophysiological
overlap between PE and PPCM may thus explain their
strong epidemiological connection.
The notion that placental sVEGFR1 triggers PPCM may
also explain 2 perplexing aspects of PPCM: ﬁrst, why the
disease affects women only during pregnancy; and second,
why the disease affects women in late pregnancy, rather than
during the second trimester when hemodynamic stresses aremost pronounced (68). In both cases, the timing matches
the secretion from the placenta of sVEGFR1 and other
antiangiogenic factors. We also found a consistently high
association between PPCM and twin pregnancies. Twin
gestations have larger placentas that secrete more sVEGFR1
into the maternal circulation (22), and twin gestations are
also an established risk factor for PE. Again, the patho-
physiological overlap between PE and PPCM may explain
these observations. Multiparity could similarly cause a step-
wise cumulative insult to cardiac function. These clinical and
experimental observations suggest a 2-hit hypothesis as
a cause of PPCM. The ﬁrst hit is the late-gestational
circulation of cardiotoxic sVEGFR1 and other anti-
angiogenic factors, and the second hit is a yet-unidentiﬁed
inability of some women’s hearts to withstand this anti-
angiogenic insult. PE and twin pregnancies accentuate the
ﬁrst hit, thus increasing the likelihood of triggering frank
PPCM.
PE and hypertensive disorders of pregnancy are also
increasingly recognized as risk factors for future
Figure 2 Prevalence Estimates for PE in Women With PPCM
Results of the meta-analysis of the primary outcome (mean prevalence and 95% conﬁdence interval [CI] of PE in women with PPCM). The red line represents the
background worldwide prevalence rate of 5%. *Reported rate 0%; 5% used for statistical purposes. Abbreviations as in Figure 1.
Figure 3 Prevalence Estimates for PE in Women With PPCM According to Country
Data are given as United States versus non–United States. Results of the meta-analysis stratiﬁed according to study country (mean prevalence and 95% CI of PE in women with
PPCM). The red line represents the background worldwide prevalence rate of 5%. *Reported rate 0%; 5% used for statistical purposes. Abbreviations as in Figures 1 and 2.
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Figure 4
Rates of PE as a Function of Prevalence of
African Heritage
Rate of PE as a function of prevalence of African heritage. Abbreviation as in
Figure 1.
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1721cardiovascular disease. A history of PE confers a >2-fold
increased risk of future cardiovascular disease (69),
a magnitude of effect that is similar to conventional risk
factors, including diabetes and dyslipidemia. American
Heart Association/American College of Cardiology guide-
lines now recommend screening for a history of PE as a part
of routine cardiovascular risk evaluation in all women (70).
The experimental data discussed here suggest that PE may
in part have direct vasculo-toxic effects that predispose to
future vascular disease, but it remains unclear whether the
increased cardiovascular risk is a direct result of the patho-
biology of PE or due to shared risk factors.
PPCM is more common and carries a worse prognosis in
women of African heritage (4,11,59). This observation has
raised the possibility that PPCM in this population may
differ from other racial backgrounds, including in its rela-
tionship to PE. We did not ﬁnd any correlation between
African ancestry and prevalence of PE in cohorts of women
with PPCM. The strength of this conclusion is somewhat
limited by the fact that data were not available at the indi-
vidual patient level, although there were high rates of women
of African descent in many of the included studies. Unfor-
tunately, only 2 studies from the Caribbean, predominantly
of African descent, reported ejection fraction data and met
inclusion criteria (5,33). Several large, high-quality studies of
PPCM from Africa excluded women with PE and were thus
also not included in the current analysis.
Study limitations. Ejection fraction in PPCM frequently
improves to near-normal, although sometimes only over
years (1–3). Few studies have evaluated factors that predict
which women will recover systolic function; low ejection
fraction on presentation is thus far the only validated
prognostic factor. Whether the presence of PE with PPCM
portends a worse or better prognosis is not known andwarrants further study. Data on outcomes were not included
in many of the studies evaluated here, and thus the corre-
lation between outcomes and incidence of PE could not be
evaluated.
Conclusions
The current study demonstrates that PE, hypertensive
disorders of pregnancy, multiple gestations, and multiparity
are strong risk factors for the development of PPCM
throughout the world. The results of the study also support
the novel concept that PE and PPCM share a common
antivascular pathobiology. PE and PPCM both contribute
to signiﬁcant cardiovascular morbidity and mortality in
women. Our analysis highlights the need for better under-
standing of the mechanistic overlap between PE and
PPCM, and a need to include patients with both PE and
PPCM in the same clinical studies. This analysis also
highlights the need for increased awareness of, and partici-
pation in, registries such as the PeriPartum CardioMyopathy
Registry of the EURObservational Research Programme by
the European Society of Cardiology. In light of potentially
unique aspects of PPCM in the United States (Fig. 2),
a similar registry in the United States would also be highly
informative, as will the results of the ongoing prospective
observational IPAC (Investigations in Pregnancy Associated
Cardiomyopathy) trial (NCT01085955).
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